澳门葡京网赌游戏 advances the science of infectious disease protection at ECCMID 2024

Beyfortus的实际有效性数据强化了被动免疫保护婴儿免受呼吸道合胞病毒住院的影响

Updated real-world data demonstrate continued risk of severe COVID-19 outcomes among immunocompromised populations

澳门葡京网赌游戏 will showcase new clinical, real-world and early science data across its Vaccines & 免疫疗法的投资组合^th 欧洲临床微生物学大会 & Infectious Diseases (ECCMID) in Barcelona, Spain from 27-30 April 2024. 该公司在此次活动中有19份摘要, including four oral presentations and four late-breaking presentations, 这将突出继续需要保护高危个体免受常见传染病负担的增加以及长效抗体和疫苗的重要作用.

数据将呈现以下特点:

• 的有效性的真实数据 Beyfortus (nirsevimab), 长效抗体, in the prevention of hospitalisation due to respiratory syncytial virus (RSV)
• 最新的现实证据表明，COVID-19感染对免疫功能低下个体的负担仍然不成比例, highlighting the need for additional protection
• Pharmacokinetic and safety data on sipavibart, an investigational long-acting antibody for the prevention of COVID-19 in immunocompromised individuals
• 早期管道资产研究, 包括一种新型mRNA-VLP疫苗平台的最新口头报告和一种预防复发的单克隆抗体的数据 C. 难相处的 感染

Iskra Reic, 执行副总裁, 疫苗和免疫疗法, 澳门葡京网赌游戏, 他说:“澳门葡京赌博游戏很高兴能在ECCMID上分享数据，展示澳门葡京赌博游戏早期和晚期疫苗和免疫疗法产品组合的进展，以及澳门葡京赌博游戏通过分化抗体和疫苗提供持久免疫力以预防传染病的雄心. 还有澳门葡京赌博游戏的创新科学, we are proud of the difference our preventative therapeutics are making in reducing the burden of respiratory 感染s, with new real-world data highlighting the effectiveness of our long-acting antibody Beyfortus in preventing infant hospitalisations due to RSV. 除了, 澳门葡京赌博游戏的数据提供的证据表明，免疫功能低下的个体继续面临COVID-19带来的严重和不成比例的负担, highlighting the need for additional protection.”

Real-world evidence highlighting the impact of Beyfortus 预防rsv相关住院
来自nse - gal的真实世界新数据, 一个研究者发起的, population-based three-year follow up study in the Galicia community in Spain, looked at the effectiveness of the 2023/2024 Beyfortus immunisation campaign in a broad infant population in reducing RSV-related hospitalisations.¹ The data add to the existing body of evidence that reinforces the high efficacy of Beyfortus 从临床试验中得出预防rsv相关下呼吸道感染住院(LRTI).

The significant burden of COVID-19 on the immunocompromised
五个报告, 包括一次口服, will highlight the ongoing risk and healthcare burden of COVID-19 on immunocompromised individuals. Data will include updated analyses from INFORM, a retrospective health database study in England, 在几个不同的免疫功能低下人群中，尽管接受了多次COVID-19疫苗接种，但发生COVID-19严重后果的风险仍在持续增加.^2-3 Real-world data from the COVIDRIVE study platform (run by the id.驱动(公私伙伴关系)强调，在欧洲，严重急性呼吸道感染的sars - cov -2阳性住院患者中，免疫功能低下的发病率高得不成比例.^4-6

澳门葡京网赌游戏在ECCMID期间的重要报告

笔记

Beyfortus
Beyfortus (nirsevimab) is a single dose long-acting antibody, 由澳门葡京网赌游戏和赛诺菲合作开发和商业化，使用澳门葡京网赌游戏的YTE延长半衰期技术. 它旨在保护在第一个RSV季节出生或进入第一个RSV季节的婴儿，以及24个月以下的儿童，他们在第二个RSV季节仍然容易患上严重的RSV疾病.  Beyfortus, provided directly to newborns and infants as a single dose, offers rapid protection via an antibody to help prevent LRTD caused by RSV, without requiring activation of the immune system.⁷

Beyfortus administration can be timed to the start of the RSV season.⁷

Beyfortus 是否被世界各地的几个主要监管机构授予监管指定，以促进加速发展. Beyfortus has been approved for use in the European Union, 并在抗菌药咨询委员会的一致建议下获得了美国食品和药物管理局的批准. Beyfortus 由免疫实践咨询委员会推荐广泛用于婴儿，并被列入美国儿童疫苗计划.⁷ Early data from the US Centers for Disease Control and Prevention, 在2023/4 RSV季节, Beyfortus was associated with a 90% reduction against RSV-associated hospitalisation among infants in their first RSV season.⁸

Sipavibart
Sipavibart (formerly AZD3152) is an investigational long-acting monoclonal antibody (LAAB) against COVID-19. Sipavibart旨在通过中和刺突蛋白与宿主受体ACE2的相互作用，在Omicron和祖先病毒变体中提供广泛而有效的覆盖.⁹

Sipavibart was derived from B-cells donated by convalescent patients after SARS-CoV-2 感染. Sipavibart has been engineered using the same antibody scaffold as Evusheld and was optimised with the same half-life extension and reduced Fc effector function and complement C1q binding platform. 减少Fc效应功能的目的是尽量减少抗体依赖性疾病增强的风险——病毒特异性抗体促进疾病增强的一种现象, 而不是抑制, 感染和/或疾病.¹⁰

Sipavibart于1998年被澳门葡京网赌游戏收购 2022年5月来自RQ生物技术.

The safety and efficacy of sipavibart is being studied in the global SUPERNOVA COVID-19 prevention trial, with data anticipated in the first half of 2024.

澳门葡京网赌游戏
澳门葡京网赌游戏 (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, 发展, and commercialisation of prescription medicines in 肿瘤学, 罕见疾病, 和澳门葡京赌博游戏, 包括心血管, 肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门葡京网赌游戏 operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 请访问 澳门葡京网赌游戏.com 并在社交媒体上关注公司 @澳门葡京网赌游戏.

联系人
For details on how to contact the 投资者关系 Team, please click 在这里. 对于“媒体联系人”，单击 在这里.

参考文献

1. 马拉等人. Universal prophylaxis with nirsevimab for prevention of infant hospitalizations due to respiratory syncytial virus. 西班牙加利西亚的一项纵向研究. 口头报告. 34^th ECCMID Global; 29 April 2024; Barcelona, Spain.
2. Dube S等. 尽管疫苗接种率很高，但多发性硬化症患者住院和死亡的风险很高:来自英格兰INFORM研究的结果. 口头报告. 34th ECCMID Global; 27 April 2024; Barcelona, Spain.
3. Dube S等. 尽管接种了4剂以上疫苗，免疫功能低下个体的COVID-19住院和死亡风险仍在持续增加:来自INFORM的2023年最新结果, a retrospective health database observational study in England. 海报P0409. 34th ECCMID Global; 27 April 2024; Barcelona, Spain.
4. Bollaerts K等. covid - rive:欧洲公私伙伴关系，旨在为COVID-19疫苗的有效性提供真实证据. 海报P0380. 34th ECCMID Global; 27 April 2024; Barcelona, Spain.
5. Meeraus W等. High prevalence of immunocompromising conditions among patients with severe acute respiratory 感染, including SARS-CoV-2: results from a multicentre, 检测阴性病例对照研究. 海报P0381. 34th ECCMID Global; 27 April 2024; Barcelona, Spain.
6. Meeraus W等. 免疫功能低, SARS-CoV-2检测呈阳性与阴性的严重急性呼吸道感染患者的癌症和其他合并症:2021年5月至2023年5月对covid - rive数据的事后分析. 海报P0382. 34th ECCMID Global; 27 April 2024; Barcelona, Spain.
7. Jones JM，等. 使用尼塞维单抗预防婴幼儿呼吸道合胞病毒疾病:免疫做法咨询委员会的建议-美国, 2023. 《凡人周刊. 2023;72(34):920-925.
8. Moline HL，等. 早期估计尼塞维单抗预防新生儿呼吸道合胞病毒相关住院的有效性-新疫苗监测网络, 2023年10月至2024年2月. 《凡人周刊. 2024;73:209–214.
9. Francica JR等人. 1355. SARS-CoV-2单克隆抗体AZD3152有效中和历史和新出现的变异，正在开发用于预防和治疗高危人群的COVID-19. 开放论坛感染Dis. 2023年11月27日;10(增刊2):500.1192. doi: 10.1093 / ofid / ofad500.1192.
10. Van Erp EA，等. Fc-媒体ted Antibody Effector Functions During 呼吸 Syncytial Virus    Infection and Disease. 前面Immunol. 2019; 10(3月).